Paxmedica inc. featured in syndicated broadcast highlighting fda type-b meeting to review pax-101 pivotal trial data

Los angeles, nov. 17, 2023 (globe newswire) -- via ibn –paxmedica, inc. (nasdaq: pxmd), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that it has been featured in a broadcast via networknewsaudio (“nna”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. the audio news release covers paxmedica's recent announcement of the completion of a type-b meeting with the fda. during the live meeting, the company discussed the positive results of the recent data from its pax-hat-301 study of suramin in stage one human african sleeping sickness caused by trypanosoma brucei rhodesiense, a rare and fatal parasitic disease if left untreated.
PXMD Ratings Summary
PXMD Quant Ranking